Literature DB >> 22504904

Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.

Dong-bo Liu1, Guang-yuan Hu, Guo-xian Long, Hong Qiu, Qi Mei, Guo-qing Hu.   

Abstract

AIM: To investigate the mechanisms underlying the anticancer effect of celecoxib on nasopharyngeal carcinoma (NPC).
METHODS: NPC cell lines, HNE1 and CNE1-LMP1, were treated with various concentrations of celecoxib for 48 h. The antiproliferative effect of celecoxib was assessed using MTT assay. Both cell cycle profiles and apoptosis were analyzed using flow cytometry. Western blot was used to measure the levels of signal transducer and activator of transcription 3 (STAT3), phosphorylated STAT3(Y705) (pSTAT3(Y705)), COX-2, Survivin, Mcl-1, Bcl-2 and Cyclin D1.
RESULTS: Celecoxib (10-75 μmol/L) inhibited the proliferation of the NPC cell lines in a dose-dependent manner. Celecoxib (25 and 50 μmol/L) induced apoptosis and cell-cycle arrest at the G(0)/G(1) checkpoint in the NPC cell lines, which was associated with significantly reduced STAT3 phosphorylation. The genes downstream of STAT3 (ie, Survivin, Mcl-1, Bcl-2 and Cyclin D1) were significantly down-regulated after exposure to celecoxib (25 and 50 μmol/L).
CONCLUSION: The anticancer effects of celecoxib on NPC cell lines results from inducing apoptosis and cell cycle arrest, which may be partly mediated through the STAT3 pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504904      PMCID: PMC4010355          DOI: 10.1038/aps.2012.18

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  52 in total

1.  Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line.

Authors:  Sebastien Arico; Sophie Pattingre; Chantal Bauvy; Pierre Gane; Alain Barbat; Patrice Codogno; Eric Ogier-Denis
Journal:  J Biol Chem       Date:  2002-05-08       Impact factor: 5.157

2.  STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signaling.

Authors:  Zhenlian Wang; Feijun Luo; Lili Li; Lifang Yang; Duosha Hu; Xiaoqian Ma; Zhongxin Lu; Lunquan Sun; Ya Cao
Journal:  Eur J Cancer       Date:  2010-08-13       Impact factor: 9.162

3.  Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis.

Authors:  Jyh-Ping Peng; Hui-Chiu Chang; Chung-Feng Hwang; Wen-Chun Hung
Journal:  Oral Oncol       Date:  2005-10       Impact factor: 5.337

4.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

5.  Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells.

Authors:  Vivian W Y Lui; Daisy M S Yau; Elaine Y L Wong; Yuen-Keng Ng; Cecilia P-K Lau; Yeung Ho; Jessica P L Chan; Bo Hong; Kakiu Ho; Crystal S Cheung; Chi-Man Tsang; Sai-Wah Tsao; Anthony T C Chan
Journal:  Carcinogenesis       Date:  2009-12       Impact factor: 4.944

6.  Knockdown of Stat3 expression using RNAi inhibits growth of laryngeal tumors in vivo.

Authors:  Li-fang Gao; Lian-ji Wen; Hao Yu; Ling Zhang; Yan Meng; Yue-ting Shao; De-qi Xu; Xue-jian Zhao
Journal:  Acta Pharmacol Sin       Date:  2006-03       Impact factor: 6.150

Review 7.  Nasopharyngeal carcinoma: current management, future directions and dental implications.

Authors:  Mark Agulnik; Joel B Epstein
Journal:  Oral Oncol       Date:  2007-12-03       Impact factor: 5.337

8.  Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax.

Authors:  René Handrick; Ute Ganswindt; Heidrun Faltin; Barbara Goecke; Peter T Daniel; Wilfried Budach; Claus Belka; Verena Jendrossek
Journal:  Radiother Oncol       Date:  2008-11-27       Impact factor: 6.280

9.  STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro.

Authors:  Vivian Wai Yan Lui; Elaine Yue Ling Wong; Yeung Ho; Bo Hong; Sze Chuen Cesar Wong; Qian Tao; Gigi Ching Gee Choi; Thomas Chi Chuen Au; Kakiu Ho; Daisy Mei Sze Yau; Brigette Buig Yue Ma; Edwin Pun Hui; Andrew Sai-Kit Chan; Chi-Man Tsang; Sai-Wah Tsao; Jennifer Rubin Grandis; Anthony Tak-Cheung Chan
Journal:  Int J Cancer       Date:  2009-10-15       Impact factor: 7.396

10.  Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.

Authors:  Gargi D Basu; Latha B Pathangey; Teresa L Tinder; Sandra J Gendler; Pinku Mukherjee
Journal:  Breast Cancer Res       Date:  2005-04-04       Impact factor: 6.466

View more
  20 in total

1.  Establishment of a novel cell-based assay for screening small molecule antagonists of human interleukin-6 receptor.

Authors:  Yang-yang He; Yu Yan; Chang Zhang; Peng-yuan Li; Ping Wu; Peng Du; Da-di Zeng; Jian-song Fang; Shuang Wang; Guan-hua Du
Journal:  Acta Pharmacol Sin       Date:  2014-10-27       Impact factor: 6.150

2.  Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.

Authors:  Justin M Reitsma; Scott S Terhune
Journal:  Antiviral Res       Date:  2013-09-23       Impact factor: 5.970

3.  Human cytomegalovirus IE1 protein disrupts interleukin-6 signaling by sequestering STAT3 in the nucleus.

Authors:  Justin M Reitsma; Hiromi Sato; Michael Nevels; Scott S Terhune; Christina Paulus
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

Review 4.  STAT3 in medulloblastoma: a key transcriptional regulator and potential therapeutic target.

Authors:  Anwar Zaiter; Zahraa F Audi; Fatima Shawraba; Zahraa Saker; Hisham F Bahmad; Rami H Nabha; Hayat Harati; Sanaa M Nabha
Journal:  Mol Biol Rep       Date:  2022-06-18       Impact factor: 2.316

5.  P300-dependent STAT3 acetylation is necessary for angiotensin II-induced pro-fibrotic responses in renal tubular epithelial cells.

Authors:  Jun Ni; Yang Shen; Zhen Wang; De-cui Shao; Jia Liu; Ya-li Kong; Lan-jun Fu; Li Zhou; Hong Xue; Yu Huang; Wei Zhang; Chen Yu; Li-min Lu
Journal:  Acta Pharmacol Sin       Date:  2014-08-04       Impact factor: 6.150

6.  The role of JAK/STAT3 signaling pathway on apoptosis of lung adenocarcinoma cell line PC-9 induced by icotinib.

Authors:  Yuping Zhang; Xia Meng; Hongyang Shi; Wei Li; Zongjuan Ming; Yujie Zhong; Wenjing Deng; Qiuhong Zhang; Na Fan; Zequn Niu; Guo'an Chen; Shuanying Yang
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

7.  Functional characterization of TRPM7 in nasopharyngeal carcinoma and its knockdown effects on tumorigenesis.

Authors:  Yi Qin; Zhi-Wei Liao; Jing-Yan Luo; Wen-Zhe Wu; An-Shang Lu; Pu-Xia Su; Bing-Quan Lai; Xiao-Xiao Wang
Journal:  Tumour Biol       Date:  2016-01-15

8.  Tonglian Decoction () arrests the cell cycle in S-phase by targeting the nuclear factor-kappa B signal pathway in esophageal carcinoma Eca109 cells.

Authors:  Yong-Sen Jia; Xue-Qin Hu; Ji-An Li; Szasz Andras; Gabriella Hegyi; Bing-Sheng Han
Journal:  Chin J Integr Med       Date:  2016-03-05       Impact factor: 1.978

9.  Inhibition of STAT3 acetylation is associated with angiotesin renal fibrosis in the obstructed kidney.

Authors:  Jun Ni; Yang Shen; Zhen Wang; De-cui Shao; Jia Liu; Lan-jun Fu; Ya-li Kong; Li Zhou; Hong Xue; Yu Huang; Wei Zhang; Chen Yu; Li-min Lu
Journal:  Acta Pharmacol Sin       Date:  2014-06-30       Impact factor: 6.150

10.  Correlation of IL-6 and JAK2/STAT3 signaling pathway with prognosis of nasopharyngeal carcinoma patients.

Authors:  Mengqi Zhuang; Xiaotong Ding; Wenli Song; Huimin Chen; Hui Guan; Yang Yu; Zicheng Zhang; Xinzhe Dong
Journal:  Aging (Albany NY)       Date:  2021-06-22       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.